References Chapter 9
Formulation and Evaluation of Nanoparticles For Better Drug Bioavailability 9-1
REFERENCES
1. Shargel L., Yu A.B., Applied Biopharmaceutics & Pharmacokinetics; 4th edi., New York: McGraw-Hill.,1999.
2. Rowland Malcolm, N. Thomas, Tozer, Clinical Pharmacokinetic
Pharmacodynamics: Concepts and Applications Philadelphia, PA: Lippincott Williams & Wilkins, 4 th edi., 2010.
3. Brahmankar D.M., Jaiswal S.B., Biopharmaceutics and Pharmacokinetic a
treatise, Vallabh prakashan, New Delhi, 2007. 4. Doornbos C.A., Haan P.D., Encyclopedia of pharmaceutical technology;
Swarbrick J, Boylan J C, Marcel Dekker, New York: 1995, 77. 5. Vyas S. P., Khar R.K, Targeted and Controlled Drug Delivery: Novel Carrier
Systems, CBS Publishers, New Delhi, 2002:331- 364. 6. Witztum J.L. Drugs used in the treatment of hyperlipoproteinemias. Goodman
and Gillman’s, The pharmacological basis of therapeutics, Mc Graw Hill, New York, 9 th edi,1996: 891-892.
7. Welling Peter G., Tse Francis L.S., Dighe Shrikant V., Pharmaceutical
Bioequivalence. Drugs and the Pharmaceutical Sciences., New York, NY: Marcel Dekker., 48 th edi.,1991.
8. Chow Shein-Chung, Liu Jen-pei, Design and Analysis of Bioavailability and
Bioequivalence Studies. Biostatistics Series. Boca Raton, FL: CRC Press., 27: 3 edi., 2008.
9. R. Govindarajan, Nagarsenker M.S., Formulation studies and in vivo evaluation
of flurbiprofen-hydroxypropyl beta-cyclodextrin system; Pharm Dev Tech. 2005; 10:105–114.
10. Heaney R.P., Factors Influencing the Measurement of Bioavailability, Taking
Calcium as a Model; J. Nutr. 131,4 Suppl: 2001:1344S-1348S. 11. Srinivasan VS., Bioavailability of Nutrients: A Practical Approach to In Vitro
Demonstration of the Availability of Nutrients in Multivitamin-Mineral Combination Products; J. Nutr. 131,4 Suppl, 2001:1349S-1350S.
12. Hoag SW, Hussain AS., The Impact of Formulation on Bioavailability:
Summary of Workshop Discussion J. Nutr. 131,4 Suppl: 2001. 13. H. Derendorf, H. Mollmann, J. Barth, C. Mollmann, S. Tunn, M. Krieg;
Pharmacokinetics and oral bioavailability of hydrocortisone; J. Clin. Pharmacol., 1991; 31: 473-476.
References Chapter 9
Formulation and Evaluation of Nanoparticles For Better Drug Bioavailability 9-2
14. Tortora G.J., principles of anatomy and physiology; 7 th edi. Harper Collins,
1993.
15. Gogate M.S., Erythromycin monograph, in chemical stability of Pharmaceuticals: A hand book for Pharmacists, (K.A. Connors, G. L. Amidon, V.J. Stella, eds), John Wiley and sons, New york, 1986, 2nd edi., 457- 463.
16. S. Yoshioka, Stella V.J., Stability of Drugs and Dosage forms, Chapter 2-
Chemical stability of drug substances, pg.no. 4. 17. Bernkop-Schnurch, Oral Drug Delivery: How do chemical reactions in the
Gastrointestinal tract influence the therapeutic potential of drugs; 2001, 1:117-228.
18. Werle M., A. Samhaber, A. Bernkop-Schnurch, Degradation of teriparatide by
gastro-intestinal proteolytic enzymes; J. Drug Target., 2006,14(3):109 -115. 19. Fuhr U., Drug interactions with grapefruit juice: extent, probable mechanism
and clinical relevance; Drug Safe 1998,18: 251-272. 20. H. Poiger, Ch. Schlatter, Compensation of dietary induced reduction of
tetracycline absorption by simultaneous administration of EDTA, Eur. J. Clin. Pharmacol., 1978, 14(2): 122-131.
21. Manthena V.S., Varma A., Y. Ashokraj, S. Chinmoy, Dey B., P-glycoprotein
inhibitors and their screening: a perspective from bioavailability Enhancement; Pharmacol. Res., 2003, 48:347-359.
22. Waterbeemd H.V., Lennernas H., Artursson P., Drug Bioavailability-Estimation
of solubility, Permeability, Absorption and bioavailability, Chapter 13- The importance of Gut wall metabolism in determining drug bioavailability, Pg. 320.
23. Hunter J., Hirst B.H., The role of P-glycoprotein and related drug efflux
systems in limiting oral absorption; Adv. Drug Deliver. Rev., 1997;25:129–57. 24. Waterbeemd H. V., H.Lennernas, P.Artursson, Drug Bioavailability-Estimation
of solubility Permeability, Absorption and bioavailability, Chapter 13 - The importance of Gut wall metabolism in determining drug bioavailability, Pg. 323.
25. The Merck manual, Online Medical library, Section: Clinical Pharmacology,
Subject: Pharmacokinetics, Topic: Bioavailability. 26. Davis M.E., Brewster M. E., Cyclodextrin-based pharmaceutics: past, present
and future; Nat. Rev. Drug Discov., 2004,3:1023-1035.
References Chapter 9
Formulation and Evaluation of Nanoparticles For Better Drug Bioavailability 9-3
27. Gwak H., Choi J., Choi H., Enhanced bioavailability of piroxicam via salt
formation with ethanolamines; Int. J. Pharm., 2005; 297:156-161. 28. Blagden N., Matas M., Gavan P.T., York P., Crystal engineering of active
pharmaceutical ingredients to improve solubility and dissolution rates; Adv. Drug Deliv. Rev., 2007; 59(7): 617-630.
29. Strickley R.G.; Solubilizing Excipients in Oral and Injectable Formulations, Pharm. Res., 2004; 21(2):200-229.
30. G. V. Murali Mohan Babu, C.D.S. Prasad, K.V. Ramana Murthy; Evaluation of
modified gum karaya as carrier for the dissolution enhancement of poorly water-soluble drug nimodipine; Int. J. Pharm., 2002, 234:1-17.
31. Water soluble pharmaceutical coating and method for producing coated
pharmaceuticals, United States Patent 5851275. 32. Lopinavir-Ritonavir: A New Protease Inhibitor: Pharmacokinetic,
Pharmacodynamic Profile, Medscape Today, Pharmacotherapy. 2001;21(11). 33. Malingre M.M., Richel D.J., Beijnen J.H., Co-administration of Cyclosporine
strongly enhances the oral bioavailability of docetaxel, J. Clin. Oncol., 2001; 19(4):1160-1166.
34. Baboota S., Shah M.S., Javed A., Ahuja A., Effect of poloxamer 188 on
lymphatic uptake of carvedilol loaded solid lipid nanoparticles for bioavailability enhancement; J. Drug Target., 2009;17(3):249-256.
35. D. Emanuele, R. Jevprasesphant, J. Penny, D. Attwood; The use of a
dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability; J. Control. Rel., 2004;95(3): 447- 453.
36. Ke W., Zhao Y., Huang R., Jiang C., Pei Y., Enhanced oral bioavailability of
doxorubicin in a dendrimer drug delivery system; J. Pharm. Sci., 2008;97(6): 2208-2216.
37. Khoo S.M., Humberstone A.J., Porter C. J. H., Edwards G.A., Formulation
design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine; Int. J. Pharm., 1998; 167(1-2):155-164.
38. Kasim NA, Whitehouse M, Ramachandran Ch, et al.; Molecular Properties of
WHO Essential Drugs and Provisional Biopharmaceutical Classification; Mol Pharm 2004; 1: 85 -96.
39. Lindenberg M, Kopp S, Dressman JB.; Classification of orally administered
drugs on the World Health Organization Model list of Essential Medicines
References Chapter 9
Formulation and Evaluation of Nanoparticles For Better Drug Bioavailability 9-4
according to the biopharmaceutics classification system; Eur J Pharm Biopharm, 2004; 58: 265-278.
40. Amidon GL, Lennernas H, Shah VP, Crison JR., A theoretical basis for a
biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability; Pharm Res, 1995; 12: 413-420.
41. Sachan NK., Bhattacharya A., S Pushkar. and Mishra A.; Biopharmaceutical
classification system: A strategic tool for oral drug delivery technology; Asian J.Pharm., 2009, 3: 76-81.
42. Amidon GL., A theoretical basis for a biopharmaceutic drug classification: the correlation of in vivo drug product dissolution and in vivo bioavailability; Pharm. Res,. 1995; 12: 425- 434.
43. Yu L.X., Amidon G.L., Polli J.L., Zhao H., Mehta M.U.; Biopharmaceutical
classification system: The scientific basis for biowaiver extensions; Pharm. Res., 2002; 19: 921-925.
44. Lipinski C.; Poor aqueous solubility an industry wide problem in drug delivery.
Am Pharm Rev., 2002; 5: 82-85. 45. Krishna A.K. and Flanagan D.R.; Micellar solubilization of a new antimalarial
drug; J. Pharm. Sci., 1989; 78: 574-577. 46. Mallick S., Pattnaik S., and Swain K., Current Perspectives of Solubilization: Potential for Improved Bioavailability; Drug Dev. Ind. Pharm., 2007; 33: 865- 873. 47. J. Hu, K.P. Johnson, Williams R.O., Nanoparticle engineering processes for
enhancing the dissolution rates of poorly water soluble drugs, Drug Dev. Ind. Pharm., 2004;30(3):233- 245.
48. Couvreur P, Vauthier C.; Nanotechnology: intelligent design to treat complex
disease; Pharm Res 2006; 23(7): 284-288. 49. Mohanraj V.J., Chen Y.; Nanoparticles - a Review, Trop J Pharm Res., 2006;
5(1): 561-573. 50. Majeti N.V., Kumar R.; Nano and microparticles as controlled drug delivery
devices; J. Pharm Sci., 2000; 3(2): 234-258. 51. N. Arunkumar, M. Deecaraman, C Rani, Nanosuspension technology and its
applications in drug delivery; Asian Journal of Pharmaceutics, 2009; 3:168-173.
References Chapter 9
Formulation and Evaluation of Nanoparticles For Better Drug Bioavailability 9-5
52. Soppimath K.; Aminabhavi T.; Kulkarni A., Rudzinski W.; Biodegradable polymeric nanoparticles as drug delivery devices; J. Control. Rel., 2001;70:1- 20.
53. Alonso M.J.; Nanoparticulate drug carrier technology, in microparticulate systems for the delivery of proteins and vaccines, Cohen S. and Bernstein H. (Eds.) Marvel Dekker, New York, 1996; 203-242.
54. Lamprecht A., Ubrich N., Perez M. H.; Biodegradable monodispersed
nanoparticles prepared by pressure homogenization-emulsification; Int. J. Pharm., 1999;184:97-105.
55. Bodmeier R., McGinity J. W.; Solvent selection in the preparation of poly (D,L-
lactide) microspheres prepared by the solvent evaporation method; Int. J. Pharma., 1988; 43: 179-186.
56. Fessi H., Dubrasquet M., Devissaguet J.H, et.al.; Pharmacokinetic evaluation of indomethacin nanocapsules; Drug Des. Del.,1989; 4: 295-302.
57. Kreuter J.; Nanoparticles in Colloidal drug delivery systems, Kreuter (Eds.)
Marvel Dekker, New York, 1994; 219-342. 58. Allemann E., Gurny R., Doelker E.; Drug-loaded nanoparticles preparation
methods and drug targeting issues; Eur. J. Pharm. Biopharm., 1993; 9: 173-191.
59. Allemann E., Doelker E. and Gurny R.; New approach for the preparation of
nanoparticles by an emulsification-diffusion method; Eur. J. Pharm. Biopharm.,1995; 40:14-18.
60. J.M. Barichello, M. Morishita, K. Takayama, T. Nagai; Encapsulation of
hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method; Drug Dev Ind Pharm., 1999; 25(4):471- 476.
61. Chothy M.F., Danenberg J. et al., Lipophillic drug loaded nanospheres
prepared by Nanoprecipitation technique: effect of formulation variables on size, drug delivery and release kinetics; J. Control. Release, 2002; 83: 389-400.
62. Allemann E., Gurny R. and Doelker E., In vitro extended-release properties of
drug-loaded poly(D,L-lactic acid) nanoparticles produced by a salting-out procedure, Pharm. Res., 1993;10:1732-1737.
63. Leroux J.C, Allemann E., De Jaeghere F., Biodegradable nanoparticles from
sustained release formulations to improved site specific drug delivery; J.Control. Rel., 1996; 39:339-350.
References Chapter 9
Formulation and Evaluation of Nanoparticles For Better Drug Bioavailability 9-6
64. Quintanar-Guerrero D, Fessi H, Allemann E, Doelker E, Influence of stabilizing agents and preparative variables on the formation of poly (D, L-lactic acid) nanoparticles by an emulsification-diffusion technique; Int J Pharm, 1996;143:133-141.
65. Calvo P., Remunan-Lopez C., Vila-Jato J. L. and Alonso M.J., J. Appl. Polym.
Sci., 1997; 63: 125-132. 66. Patel Paresh N., Patel L. J. and Patel J. K., Development and testing of novel
temoxifen citrate loaded chitosan nanoparticles using ionic gelation method; Der Pharmacia Sinica, 2011; 2 (4):17-25.
67. Kafshgari Morteza Hasanzadeh, Khorram Mohammad, Khodadoost Mobina,
and Khavari Sahar, Reinforcement of Chitosan Nanoparticles Obtained by an Ionic Cross-linking Process; Iranian Polymer Journal, 2011;20(5): 445-456.
68. Shu X.Z., Zhu K.J.; A novel approach to prepare tripolyphosphate /chitosan
complex beads for controlled drug delivery; Int. J. Pharm., 2000; 201:51-58. 69. Mi FL, Shyu S., Lee S., Wong S.T., Kinetic study of chitosan-tripolyphosphate
complex and acid resistive properties for the chitosan-tripolyphosphate gel beads prepared by in-liquid curing method.; J. Polym. Sci. Polym. Phys., 1999; 37:1551-1564.
70. Lim L.Y., Wan L.S., Thai P.Y., Chitosan microspheres prepared by
emulsification and ionotropic gelation; Drug Dev. Ind. Pharm., 1997;23: 981-985.
71. S. Shiraishi, T. Imai, M. Otagiri, Controlled release of indomethacin by
chitosan-polyelectrolyte complex: optimization and in vivo/in vitro evaluation; J. Control. Release,1993;25:217-225.
72. Bodmeier R.H., Parmar K.H., preparation and evaluation of drug containing
chitosan beads; Drug. Dev. Ind. Pharm. 15:1475-1494. 73. Krishna Sailaja , A. Amareshwar; Preparation of chitosan coated nanoparticles
by emulsion polymerization technique; Asian Journal of Pharmaceutical and Clinical Research, 2011; 4(1): 73-74.
74. Coester C., Langer K., Kreuter J.; Gelatin nanoparticles by two step desolvation
a new preparation method, surface modifications and cell uptake; J. Microencapsulation, 2000;17:187-193.
75. Hwang S.J, Jun S.W., Kim M.S, Kim J.S, Park H.J., Lee S., Woo J.S.; Preparation
and characterization of simvastatin/hydroxypropyl-b-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process; European Journal of Pharmaceutics and Biopharmaceutics, 2007; 66: 413- 421.
References Chapter 9
Formulation and Evaluation of Nanoparticles For Better Drug Bioavailability 9-7
76. Turk M., Hils P., Helfgen B., Schaber K., Martin H., Wahl M.A.; Micronization of
pharmaceutical substances by the Rapid Expansion of Supercritical Solutions (RESS): A promising method to improve bioavailability of poorly soluble pharmaceutical agents; J Supercrit Fluids, 2002; 22:75-84.
77. Mehta Ashish K., Yadav K.S., Sawant Krutika K., Nimodipine Loaded PLGA
Nanoparticles: Formulation Optimization Using Factorial Design, Characterization and In Vitro Evaluation; Current Drug Delivery, 2007; 4:185-193.
78. Santander Ortega M.J., Jodar Reyes A.B., Csaba N., et al.; Colloidal stability of
Pluronic F68-coated PLGA nanoparticles: A variety of stabilisation mechanisms; J Colloid Interface Sci., 2006;302:522-529.
79. Gliding D.K., Reed A.M.; Biodegradable polymers for used in surgery,(poly
glycolic acid/ polylactic acid) homo and copolymers, Polymer; 1979, 20:1459-1464.
80. Santander Ortega M.J., Jodar-Reyes A.B., Csabac N., et al., Colloidal stability of
Pluronic F68-coated PLGA nanoparticles: A variety of stabilisation mechanisms; Journal of Colloid and Interface Science, 2006; 302:522-529.
81. Koa J.A., Park H.J., Hwang S.J., Park J.B., Lee J.S., Preparation and characterization of chitosan microparticles intended for controlled drug delivery; International Journal of Pharmaceutics, 2002; 249:165-174.
82. Joseph Nisha Mary and Sharma Pramod Kumar, Cross-linked nanoparticles of
cytarabine: encapsulation, storage and in-vitro release; African Journal of Pharmacy and Pharmacology, 2007;(1):10-13.
83. Langer K., Zimmer A., Kreuter J., etal., Characterisation of
polybutylcyanoacrylate nanoparticles: I. Quantification of PBCA polymer and dextrans; Int. J. Pharm., 1994; 110:21-27.
84. Magenheim B. and Benita S., Nanoparticle characterization: a comprehensive
physicochemical approach; Pharma Sciences, 1991;1:221-241. 85. Krause K. P. and Muller R. H.; Production and characterization of highly
concentrated nanosuspensions by high pressure homogenization; Int. J. Pharm., 2001; 214:21-24.
86. Delgado V., Gonzalez-Caballero F., Hunter R. J., Koopal L. K., Lyklema J.,
Measurement and Interpretation of Electrokinetic Phenomena (IUPAC Technical Report). Pure Appl. Chem. 2005; 77 (10): 1753-1850.
References Chapter 9
Formulation and Evaluation of Nanoparticles For Better Drug Bioavailability 9-8
87. Barratt G., Characterization of colloidal drug carrier systems with zeta potential measurements. Pharm Technol Eur, 1999;1:25-32.
88. Rawle A., (Malvern Instruments Limited, Enigma business Park, Grove wood
Road, Malvern, Worcestershire, UK). Basic principles of particle size analysis. Technical paper. Malvern Instruments; Report No.: MRK034.
89. Lipid research Clinical Program, The Lipid Research Clinics Coronary Primary
Prevention Trial Results: reduction in incidence of Coronary heart disease, JAMA, 1984: 251-351.
90. Godkar Praful B., Godkar Darshan P., Medical laboratory technology, Bhalani
publishing house, Mumbai, 2006; 2: 352-380. 91. Framer J.A., Gotto A.M., Dyslipidemia and other risk factors for coronary
artery disease, cardiovascular medicine, W.B. Saunders, 1997:5. 92. Gaw A., Packard C.J., Comparative chemistry, pharmacology and mechanism
of action of the statins, J. Statins. The HMG CoA reductase inhibitors in perspective, Martin Dunitz, London, 2000: 49-61.
93. Corsini A., Maggi F.M., Catapano A.L.; Pharmacology of competitive inhibitors
of HMG-CoA reductase., Pharmacol. Res. 1995; 31: 9-27. 94. Lennernas H., Fager G., Pharmacodynamics and pharmacokinetics of the
HMG-CoA reductase inhibitors., Clin. Pharmacokinet.,1997; 32:403-425.
95. Shepherd J., Hunninghake D.B., Barter P., McKenney J.M., Hutchinson H.G., Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of Rosuvastatin with Atorvastatin, Pravastatin, and Simvastatin for achieving lipid-lowering goals; Am J Cardiol 2003; 91(Suppl 1):11C-19C.
96. Ramani Vinod, Chuhan Sachin, Joshi Jibin, Ghelani Tejas, Deshmukh, Gajanan
formulation and evaluation of nanoparticles of hmg -coa reductase inhibitor; International Journal of Pharmaceutical Sciences, 2011;1(1):1135-1151.
97. Patil Mukesh S., Bavaskar Kedar R. et al., Preparation and optimization of
simvastatin nanoparticle for solubility enhancement and in- vivo study; International journal of Pharma research and development, 2011; 2(12):219-226.
98. Zhanga Z., Bua H., Gaoa Z., Huanga Y., Gaoa F., Li Y., The characteristics and
mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats; Int J Pharm 2010;394:147-53.
References Chapter 9
Formulation and Evaluation of Nanoparticles For Better Drug Bioavailability 9-9
99. Pandya Vikram M., Patel Jayvadan K and Patel Dhaval J., Formulation, Optimization and characterization of simvastatin nanosuspension prepared by nanoprecipitation technique; Der Pharmacia Lettre, 2011, 3(2): 129-140.
100. V. Devi Kusum, Bhosale U.V., formulation and optimization of polymeric nano
drug delivery system of acyclovir using 3² full factorial design; International Journal of PharmTech Research, 2009; 1(3), 644-653.
101. Patil Pradeep, Patil Vandana, Paradkar Anant, Formulation of a self-
emulsifying system for oral delivery of simvastatin: In vitro and in vivo evaluation; Acta Pharm., 2007; 57: 111–122.
102. Dustgania Amir, Farahania Ebrahim Vasheghani, Imanib Mohammad,
Preparation of Chitosan Nanoparticles Loaded by Dexamethasone Sodium Phosphate; Journal of Pharmaceutical Sciences, 2008; 4(2):111-114.
103. Chen Weiyang, Cross-linked chitosan in mini-tablets for controlled drug
release by, school of phamarcy, faculty of health sciences tshwane university of technology, (M. Tech) dissertation, 2005.
104. Xiaomei Wang, Na Chi, Xing Tang; Preparation of estradiol chitosan
nanoparticles for improving nasal absorption and brain targeting; European Journal of Pharmaceutics and Biopharmaceutics, 2008;70:735–740.
105. Bhumkar Devika R., Pokharkar V.B.; Studies on effect of pH on cross-linking of
chitosan with sodium tripolyphosphate; AAPS Pharmasci Tech: 2006; 7(2): 50. 106. Saha Partha, Goyal Amit K. and Goutam Rath, Formulation and Evaluation of
Chitosan-Based Ampicillin Trihydrate Nanoparticles; Tropical Journal of Pharmaceutical Research, 2010; 9 (5): 483-488.
107. Nanjwade Basavaraj K., Derkar Ganesh K., Bechra Hiren M., Nanjwade Veerendra K. and Manvi F.V., Design and Characterization of Nanocrystals of Lovastatin for Solubility and Dissolution Enhancement; J Nanomedic Nanotechnol 2011, 2:2.
108. Zlatko Pflaum, Domzale, Mateja Salobir et al, Boston, USA, Solid
pharmaceutical formulation containing lovastatin and simvastatin and it’s preparation.:US patent application no.US/2004/0138295A1 dated 15 July 2004.
109. Company literature on ZOCOR® (Simvastatin) Tablets. NJ, USA: Merck and
Co., Inc; 2004:1-12.
References Chapter 9
Formulation and Evaluation of Nanoparticles For Better Drug Bioavailability 9-10
110. Astete C. E. and Sabliov C. M.; Synthesis and characterization of PLGA nanoparticles; Journal of Biomaterials Science - Polymer Edition, 2006;17(3): 247–289.
111. Agnihotri S.A., Mallikarjuna N.N., Aminabhavi T.M., Recent advances on
chitosan based micro and nanoparticles drug delivery; Journal of controlled release; 2004;100: 5-28.
112. BASF Corporation, 3000 Continental Drive-North Mount Olive, New Jersey. 113. Gan et al., Modulation of surface charge, particle size and morphological
properties of chitosan-TPP nanoparticles intended for gene delivery; Colloids and Surfaces B: Biointerfaces, 2005; 44:65-73.
114. Wand Asgharnejad M, Second Derivative UV Spectrometric determination of
simvastatin in its tablet dosage form; Journal of Pharmaceutical and Biomedical Analysis 2000; 21: 1243-1248.
115. Nirogi R., Mudigonda K., Kandikere V., Chromatography-mass spectrometry
methods for the quantitation of statins in biological samples; J Pharm Biomed Anal, 2007;44:379-387.
116. Shyu S.S., Kuan C.Y., Lee S.T., Lu K.T., Jang S.F., Chitosan polyelectrolyte
complexation for the preparation of gel beads and controlled release of anti- cancer drug. Enzymatic hydrolysis of polymer; J. Appl. Polym. Sci., 1990; 74:1868-1879.
117. Panyam J., Dali M.M., Sahoo S.K., et al.; Polymer degradation and in vitro
release of model protein from poly (D, L-lactide-co-glycolide) nano- and microparticles; J Control Rel., 2003;92:173-187.
118. Mukdavan Prakobvaitayakit and Ubonthip Nimmannit; Optimization of
Polylactic-Co-Glycolic Acid Nanoparticles Containing Itra-conazole Using 23 Factorial Design; AAPS PharmSciTech 2003;4(4):1-9.
119. Stetsko G., Statistical experimental design and its application to
pharmaceutical development problems; Drug Dev Ind. Pharm., 1986; 12:1109-1123.
120. Souto E. B., Muller R. H., Nanoparticles for Pharmaceutical Applications; Domb A, Tabata Y, Kumar R, Eds.; American Scientific Publishers, 2006:103.
121. Hecq J., Deleers M, Fanara D., Vrandex H., Amighi K., Preparation and
characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine; International Journal of Pharmaceutics, 2005; 299: 167-177.
References Chapter 9
Formulation and Evaluation of Nanoparticles For Better Drug Bioavailability 9-11
122. Kocbek P, Baumgartner S., Kristi J., Preparation and evaluation of
nanosuspensions for enhancing dissolution of poorly soluble drugs; International Journal of Pharmaceutics, 2006; 312(1-2):179-186.
123. Lourenco C, Teixeira M, Simees S, Gaspar R., Steric stabilization of
nanoparticles: Size and surface properties; Int J Pharm 1996;138:1-12. 124. Lewis G A, Mathieu D, Phan-Tan-Luu R, Pharmaceutical experimental design:
Drugs and Pharmaceutical Sciences; Marcel Dekker,; New York: 1999, 1st edi.; 235.
125. Wedad Ashour Fourjani, In vitro anticancer properties of linamarin
controlled release from biodegradable poly-lactic co-glycolic acid nanoparticle, Universiti Putra Malaysia, 2005.
126. Yuichi T., Atsutoshi I., Hiiroko S., Toshio O., Keiji Y., Characterization and
quantitation of Clarithromycin polymorphs by powder X-Ray diffractometry and solid state NMR spectroscopy; Chemical & Pharmaceutical Bulletin 2002; 50:1128-1130.
127. Kristi J., Baumgartner S., Planinsek O., Dolenc A.; Advantages of celecoxib
nanosuspension formulation and transformation into tablets; International Journal of Pharmaceutics, 2009;376(1-2): 204-212.
128. S. Magdassi and G.K Margulis; Formation of simvastatin nanoparticles from
microemulsion; Nanotechnology, Biology and Medicine in Nanomedicine, 2009;5: 274-281.
129. Dubey Arunkumar, Ahalya Devi, Kutty Gopalan and Pathiyil Ravi,
Hypolipidemic Activity of Ginkgo biloba Extract, EGb 761 in Hypercholesterolemic Wistar Rats; Iranian Journal of Pharmacology & Therapeutics, 2005; 4:9-12.
130. Cheng H., Sutton S. C., Pipkin J. D., Zentner G. M., Rogers J. D., Evaluation of
sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors in dogs and humans; Pharm.Res. 1993;10:1683-1687.
131. Ambike A., Mahadik K. R. and Paradkar A.R.; Spray dried amorphous solid
dispersions of simvastatin; a low Tg drug: In vitro and in vivo evaluations; Pharm. Res., 2005; 22:990-998.
132. Guidance for industry, estimating the maximum safe starting dose in initial
clinical trials for therapeutics in adult healthy volunteers US department of health and human services, FDA centre for drug evaluation and research (CDER), July 2005, Pharmacology and Toxicology.
References Chapter 9
Formulation and Evaluation of Nanoparticles For Better Drug Bioavailability 9-12
133. Nirogi Ramkrishna, Mudigonda Koteshwara, Kandikere Vishwottam,
Chromatography- mass spectrophotometry methods for the quantitation of statin in biological samples; Journal of Pharmaceutical and Biomedical Analysis, 2007, 44: 379- 387.
134. Madan P.L.; Biopharmaceutics and Pharmacokinetic, Jaypee publication, New
Delhi, 2000;1: 233-282. 135. Bhasir Sajid, Jamshaid Mohammad, Ahmed Bhasir, Pharmacokinetic of
ciprofloxacin in Normal rabbits and changes observed in induced dehydrate state; Pak. J. Pharm. Sci. 2008; 21(3):225- 229.
136. Khoo S. M., Humberstone A.J., Porter C.J. H, Edwards G.A., Charman W. N.,
Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine, Int. J. Pharm, 1998;167: 155-164.
137. International Conference on the Harmonization of Technical Requirements
for the Registration of Pharmaceuticals for Human Use (ICH) Q2B; Validation of Analytical Procedures: Methodology, November 6, 1996; London, UK.
138. ICH QIA (R2), Stability testing guidelines: Stability testing of new drug
substances and products, The European agency for the evaluation of medicinal products. 2003, CPMP/ICH/273/99:4-20.
139. Yoshioka S., Stella V. J., Stability of Drugs and Dosage forms, Chapter 2-
Chemical stability of drug substances, pg.no. 4. 140. Nti-Gyabaah J, Chmielowski R, Chan V, Chiw Y.C.; Solubility of lovastatin in a
family of six alcohols: Ethanol, 1-propanol, 1-butanol, 1-pentanol, 1-hexanol and 1-ioctanol. Int J Pharm., 2008;359:111-117.
141. Brenner G.S., Ellison D.K. and Kaufman M.J.; Lovastatin. In: Brittain HG (ed.)
Analytical Profiles of Drug Substances. Academic Press Inc., California, 2005: 277-305.
142. R. Sureshkumar, Subhashish Debnath, GNK Ganesh; Chitosan nanoparticles
by Ionotropic Gelation containing L- Arginine; Research J. Pharm. And Tech. 2009;2(1): 80-85.
143. Calvo P., Remunan Lopez, C. Vila Jato J.L. and Alonso M. J., J. Appl. Polym.
Sci., 1997;63:125-132. 144. Shiraishi S., Imai T., Otagiri M.; Controlled release of Indomethacin by
chitosan-polyelectrolyte complex: optimization and in vivo/in vitro evaluation; J. Control. Release, 1993;25:217-225.
References Chapter 9
Formulation and Evaluation of Nanoparticles For Better Drug Bioavailability 9-13
145. Pan H.Y., DeVault A.R., Wang Iverson D., Ivashkiv E., Swanson B.N., Comparative pharmacokinetics and pharmacodynamics of Pravastatin and Lovastatin; J. Clin. Pharmacol., 1990;30:1128-1135.
146. G. Suresh, K. Manjunath, V. Venkateswarlu, V. Satyanarayana, Preparation,
Characterization, and In Vitro and In Vivo Evaluation of Lovastatin Solid Lipid Nanoparticles; AAPS PharmSciTech 2007; 8 (1) Article 24, E1-E9.